Abstract
Summary of baseline characteristics, treatment regimens, hematologic and cardiac responses, and survival outcomes among 51 patients with Mayo stage IIIb AL amyloidosis treated with daratumumab‐based frontline therapy.
1. Introduction
The introduction of the anti‐CD38 monoclonal antibody daratumumab transformed treatment in AL amyloidosis, with the pivotal ANDROMEDA trial establishing Dara‐VCd (daratumumab‐cyclophosphamide‐bortezomib‐dexamethasone) as standard frontline therapy [1]. However, patients with stage IIIb disease, defined as NT‐proBNP ≥ 8500 ng/L per the European modification of the Mayo 2004 staging system, were excluded from ANDROMEDA and other clinical trials [2]. This subgroup has historically poor outcomes, with median OS of ~4–5 months [3, 4]. Although emerging real‐world data and prospective single‐arm studies using daratumumab‐based regimens in this population have reported favorable outcomes compared with historical data, published follow‐up data remain limited [5, 6, 7, 8, 9, 10, 11, 12, 13]. We previously published the feasibility of Dara‐VCd (with clinician‐directed dose reductions of bortezomib and dexamethasone) in 22 patients with stage IIIb AL demonstrating hematologic response rates comparable to ANDROMEDA and 1 year OS of ~68% at 11.8 months median follow‐up [5].
Long‐term outcomes in Mayo stage IIIb AL amyloidosis treated with daratumumab‐based frontline therapy remain incompletely characterized. In this context, we performed a two‐center retrospective cohort study of all consecutive patients with Mayo stage IIIb systemic AL amyloidosis treated with frontline daratumumab‐based therapy (Dara‐VCd or Dara‐Vd) at Columbia University Irving Medical Center (CUIMC; New York, NY) and University of Medicine and Pharmacy Carol Davila (Bucharest, Romania) through April 2025. Clinical and laboratory data were abstracted from the electronic medical record following Institutional Review Board approval with waiver of informed consent.
Hematologic and organ responses were assessed per consensus guideline criteria [14, 15, 16, 17, 18]. Responses were assessed at predefined landmark time points and at best response; hematologic best response was assessed with respect to first‐line therapy, while organ best response was assessed at any time after treatment initiation irrespective of lines of therapy. Patients who died prior to assessment were classified as nonresponders in an intention‐to‐treat analysis. Supplemental methods provide further methodological details.
Fifty‐one consecutive patients with Mayo stage IIIb AL amyloidosis were included. Baseline demographic and clinical characteristics are summarized in Table 1. Median age was 64.7 years and 66.7% were male. Most patients presented with advanced cardiac dysfunction, including NYHA class III/IV symptoms in 63.2%, median NT‐proBNP of 14 036 pg/mL, median high‐sensitivity troponin‐T (hs‐TnT) of 119 ng/L, and systolic blood pressure < 100 mmHg in 31.4%. Extracardiac organ involvement was common, most frequently involving the kidneys and liver. Median dFLC was 56.7 mg/dL, and 15.7% met SLiM‐CRAB criteria for coexistent myeloma. Most patients received Dara‐VCd (92.2%); no patients underwent upfront autologous transplantation.
TABLE 1.
Baseline demographic and clinical characteristics of the study cohort [N = 51].
| Variable | Median (range), unless otherwise specified |
|---|---|
| Age, years | 64.7 (40.4–92.2) |
| Sex, male (%; n/N) | 66.7 (34/51) |
| Ethnicity (%; n/N): | |
| Hispanic | 8 (4/50) |
| Non‐Hispanic | 92 (46/50) |
| Race (%; n/N): | |
| White | 78 (39/50) |
| Black | 12 (6/50) |
| Asian/Pacific Islander | 4 (2/50) |
| Other | 6 (3/50) |
| Mayo 2012 stage, (%; n/N) | |
| Stage 3 | 21.6 (11/51) |
| Stage 4 | 78.4 (40/51) |
| NYHA class (%; n/N) | |
| I | 2 (1/49) |
| II | 34.7 (17/49) |
| III | 42.8 (21/49) |
| IV | 20.4 (10/49) |
| ECOG performance status (%; n/N): | |
| 0 | 0 (0) |
| 1 | 37.1 (13/35) |
| 2 | 34.3 (12/35) |
| 3 | 11.4 (4/35) |
| 4 | 17.1 (6/35) |
| Other involved organs (%; n/N) | |
| Kidney | 60.8 (31/51) |
| Liver | 27.4 (14/51) |
| Number of organs involved | 2 (1–7) |
| Laboratory values | |
| Serum albumin, g/dL | 3.3 (1.7–4.9) |
| LDH > ULN (%; n/N) | 67.4 (29/43) |
| Serum creatinine (mg/dL) | 1.28 (0.5–8.26) |
| 24‐h urine protein, g | 1.51 (0.0–28.1) |
| dFLC (mg/dL) | 56.7 (6.6–906.9) |
| dFLC > 18 mg/dL (%; n/N) | 80.4 (41/51) |
| NT‐proBNP (pg/mL) | 14 036 (8565–70 000) |
| Log (NT‐proBNP) | 9.5 (9.1–11.2) |
| High‐sensitivity troponin‐T (ng/L) | 119 (50–3119) |
| IVS thickness, cm | 1.5 (1.1–2.4) |
| Systolic BP < 100 mmHg | 31.4 (16/51) |
| LVEF, % | 50 (15–70) |
| Percent BMPCs | 15 (0–70) |
| Patients with concomitant MM by SLiM‐CRAB criteria (%; n/N) | 15.7 (8/51) |
| FISH cytogenetics (%; n/N) | |
| t(11;14) | 40 (16/40) |
| Gain/Amp(1q) | 22.2 (8/36) |
| Del(1p) | 8.8 (3/34) |
| Hyperdiploidy | 36.1 (13/36) |
| Del(13q) or monosomy 13 | 27.3 (9/33) |
| High‐risk myeloma translocations or Del(17p) | 9.1 (4/44) |
| Frontline treatment regimen (n, %) | |
| Dara‐VCd | 92.2 (47/51) |
| Dara‐Vd | 7.8 (4/51) |
Abbreviations: BMPC, bone marrow plasma cells; BP, blood pressure; Dara‐VCd, daratumumab, bortezomib (Velcade), cyclophosphamide, dexamethasone; Dara‐Vd, daratumumab, bortezomib (Velcade), dexamethasone; dFLC, difference between involved and uninvolved free light chain; ECOG, Eastern Cooperative Oncology Group; IVS, interventricular septum; LDH, lactate dehydrogenase; LVEF, left ventricular ejection fraction; MM, multiple myeloma; NT‐proBNP, N‐Terminal Pro Brain Natriuretic Peptide; NYHA, New York Heart Association; SLiM‐CRAB, S (bone marrow plasmacytosis of greater than or equal to 60%), Li (involved/uninvolved serum free light chain ratio of 100), M (more than one focal lesion on an MRI), C (hypercalcemia), R (renal/kidney damage), A (anemia), B (bone lesions); ULN, upper limit of normal.
Among 41 patients from CUIMC with available hospitalization data, 18 (43.9%) initiated treatment in the inpatient setting. Most patients (35/41; 85.4%) had ≥ 1 hospitalization within the first‐year after treatment initiation, with a median of one hospitalization per patient (range, 0–9). The median time to first hospitalization was 0.53 months (range, 0–10.8). Overall, 81 hospitalizations occurred among 41 patients, most commonly due to cardiovascular causes (51/81, 63%), followed by infections (21/81, 25.9%) (Table S1).
Hematologic responses deepened over time (Figure 1a). Hematologic ≥ VGPR increased from 26.1% (n = 12/46) at 1 month to 44.8% (n = 22/49) at 6 months and 54.9% (n = 28/51) at best response to frontline therapy, while hematologic CR increased from 8.7% (n = 4/46) to 22.4% (n = 11/49) and 33.3% (n = 17/51), respectively. Among evaluable patients, achievement of dFLC < 1 mg/dL and iFLC < 2 mg/dL increased over time, reaching 65.4% at 6 months for both measures. The median time to best hematologic response was 2.7 months (range, 0.4–14.0).
FIGURE 1.
Hematologic and organ responses over time among patients with Mayo stage IIIb AL amyloidosis treated with daratumumab‐based frontline therapy. Stacked bars depict the proportion of evaluable patients achieving each response category over time. Panel A depicts hematologic responses (complete response [CR; dark red], very good partial response [VGPR; orange‐red], partial response [PR; light orange], or no response [NR]/progression/death [pale peach]) at 1, 3, and 6 months, and at best response, assessed per International Society of Amyloidosis (ISA) criteria. Panel B depicts cardiac responses (complete response [CR; dark teal‐green], very good partial response [VGPR; medium teal], partial response [PR; light teal], or no response [NR]/progression/death [pale gray‐blue]) at 3, 6, and 12 months, and at best response, assessed per consensus criteria. Patients who died prior to a given time point were classified as nonresponders. The number of evaluable patients at each time point is indicated. [Color figure can be viewed at wileyonlinelibrary.com]
Cardiac responses (Figure 1b) were modest but clinically meaningful. A total of 48/51 patients were evaluable for best cardiac response; two were non‐evaluable due to heart transplantation, and one was lost to follow‐up. At 3 months, 32.6% (14/43) achieved a cardiac response (≥ PR), including 25.6% VGPR (11/43). At 6 months, 34.8% (16/46) had ≥ cardiac PR, including 23.9% VGPR (11/46) and 2.2% CR (1/46). At 12 months, 37.8% (17/45) achieved ≥ PR, including 22.2% VGPR (10/45) and 4.4% CR (2/45). The median time to first cardiac response was 2.5 months (range, 0.4–28.9) and the median time to best cardiac response was 17.8 months (range, 1.6–63.1). Best cardiac response included CR in 8.3% (4/48), VGPR in 27.1% (13/48), and PR in 4.2% (2/48), while 60.4% had no response/progression. The median NT‐proBNP at baseline for patients who achieved cardiac ≥ PR versus those with < PR was 10 507 pg/mL (IQR, 9653‐21 904) and 19 675 pg/mL (IQR, 10377.5‐31669.5) respectively (p = 0.08).
Among 31 surviving patients alive at 3 months with available data on subsequent cardiac progression, 11 (35.5%) experienced cardiac progression (9 by NT‐proBNP criteria, two by troponin criteria, and five by LVEF criteria). The risk of cardiac progression stratified by best cardiac response was 0/4 for cardiac CR, 2/13 for VGPR, and 2/2 for PR. The median OS in patients with cardiac progression at any time point after the 3‐month landmark was 25.9 months (95% CI, 3.4–35.5) versus not reached (95% CI, NR‐NR) in those without progression (p = 0.0012).
Among 23 evaluable patients, 39.1% (n = 9) achieved a renal response, including two CR, five VGPR, and two PR at best response; median time to first renal response was 5.2 months (range, 2.9–13.3), and the median time to best renal response was 11.9 months (range, 2.9–26.3).
At a median follow‐up of 37.3 months (95% CI, 21.8–41.5), median OS for the entire cohort was 12.9 months (95% CI, 2.9–35.5) (Figure 2a). Estimated survival rates at 6, 12, 24, and 36 months were 54.9% (95% CI, 41.2–67.9), 50.7% (95% CI, 37.2–64.1), 44.0% (95% CI, 30.9–58.0), and 33.2% (95% CI, 20.2–49.4). Median MOD‐PFS was 4.79 months (95% CI, 2.0–19.4) (Figure 2b). On univariate analysis, NYHA functional class at diagnosis and log‐transformed NT‐proBNP were significantly associated with OS (Table S2). On multivariate analysis, compared with NYHA class I/II, the hazard ratio (HR) for mortality for NYHA class III/IV was 3.08 (95% CI, 1.25–7.57; p = 0.0141), and the HR for each one‐unit increase in log NT‐proBNP was 1.89 (95% CI, 1.07–3.23; p = 0.0215). Notably, estimated 3‐year OS was 60.2% for NYHA class I/II versus 18.8% for NYHA class III/IV (p = 0.006) (Figure 2c).
FIGURE 2.
Kaplan–Meier analyses of survival outcomes in Mayo stage IIIb AL amyloidosis treated with daratumumab‐based frontline therapy. Kaplan–Meier curves depict survival outcomes from the time of treatment initiation. Panels A and B show 95% confidence intervals (CI) as shaded regions. The number of patients at risk at each time point is indicated. Panel A depicts overall survival (OS). Panel B depicts MOD‐PFS, defined as time to death, end‐stage cardiac or renal disease, or hematologic or organ progression, whichever occurred first. Panel C depicts OS stratified by New York Heart Association (NYHA) functional class; the red curve represents patients with NYHA Class I (n = 1; 2.0% of the cohort) or II (n = 17; 37.7%), whereas the blue curve represents patients with NYHA Class III (n = 21; 42.8%) or IV (n = 10; 20.4%). Compared with NYHA Class I/II, NYHA Class III/IV was associated with increased mortality (hazard ratio [HR], 3.08; 95% CI, 1.25–7.57; p = 0.0141). Estimated 3‐year OS was 60.2% for NYHA Class I/II versus 18.8% for NYHA Class III/IV (p = 0.006). [Color figure can be viewed at wileyonlinelibrary.com]
Second‐line clone‐directed therapy was initiated in 35.3% (18/51) of patients, either for suboptimal hematologic response to frontline daratumumab‐based therapy (n = 10) or hematologic progression/relapse (n = 8), but none for toxicity. The most common second‐line therapy was venetoclax‐based (n = 8), followed by daratumumab in combination with immunomodulatory drugs (n = 4).
This two‐center study represents one of the largest and longest‐followed real‐world stage IIIb cohorts reported to date. Outcomes appear improved compared with historical pre‐daratumumab cohorts, but substantially inferior to those observed in stage I‐IIIa disease in ANDROMEDA [1]. We demonstrate that cardiac CR, which is associated with long‐term survival comparable to age‐ and sex‐matched controls [19], is achievable in approximately one in 10 patients with stage IIIb disease. Importantly, those with NYHA class I/II symptoms at presentation have promising long‐term survival despite meeting Mayo stage IIIb criteria and therefore should not be routinely excluded from clinical trials.
Hematologic responses deepened over time, with ≥ VGPR achieved in ~55% of patients and hematologic CR in one‐third at best response. Although Shen et al. reported a higher hematologic CR rate of 65% among stage IIIb patients treated with Dara‐Vd, cross‐study comparisons are limited by differences in patient selection, including exclusion of co‐diagnosed multiple myeloma, lower baseline dFLC, and fewer patients with NYHA class IV symptoms [13]. Early achievement of a deep hematologic response is increasingly recognized as a clinically meaningful early end point; as such, prospective studies continue to evaluate emerging therapies that may achieve more rapid hematologic responses than Dara‐VCd, such as etentamig, a BCMA‐targeting bispecific antibody that reported a median time to hematologic CR of 0.9 months [20]. Cardiac responses, well‐established as a prognostic factor in AL amyloidosis, accumulated more gradually, with ~40% achieving ≥ cardiac PR at best response, including 8.3% with cardiac CR. These hematologic and cardiac response findings are broadly consistent with retrospective and prospective studies evaluating daratumumab‐based therapy in stage IIIb disease, although differences in eligibility criteria and baseline disease severity likely contribute to variability in reported outcomes (Table S3). Notably, reported rates appear lower than those previously reported by our group [5], likely due in part to methodological differences; the current analysis utilizes intention‐to‐treat reporting whereas our prior analysis included only patients alive at each assessment time point. Critically, cardiac responses were largely limited to patients achieving deep hematologic responses (14/19 patients with cardiac ≥ PR had achieved heme ≥ VGPR), reinforcing the importance of rapid suppression of toxic light chain production in AL amyloidosis.
Survival (median OS of 12.9 months in our cohort) appears improved compared with outcomes reported in pre‐daratumumab cohorts from the 2010s (median OS 4–6 months). Early cardiovascular hospitalizations remained common. NYHA functional class and NT‐proBNP remained strongly associated with survival, consistent with prior studies.
Limitations include the retrospective design and potential referral bias; few patients received Dara‐Vd, limiting regimen‐specific comparisons. Nevertheless, strengths include the consecutive nature of the cohort, uniform frontline use of daratumumab‐based therapy, intention‐to‐treat analysis, and extended follow‐up.
Taken together, these findings support daratumumab‐based frontline therapy as an effective treatment approach for Mayo stage IIIb AL amyloidosis while underscoring the continued need for prospective studies specifically designed for this high‐risk population.
Funding
The authors have nothing to report.
Conflicts of Interest
The authors declare no conflicts of interest.
Supporting information
Data S1: ajh70416‐sup‐0001‐Supinfo.docx.
Table S1: 1st year hospitalization data attached separately as Table S1 CUIMC hospitalization Data.pdf Table S1. First‐year hospitalization data for 41 patients following treatment initiation at Columbia University Irving Medical Center (CUIMC).
Table S2: Univariate analysis for overall survival (OS) using Cox proportional hazards models attached separately as Table S2 univariate analysis Cox.pdf Table S2. Univariate analysis of factors associated with overall survival (OS) using Cox proportional hazards models.
Table S3: Mini‐review of key studies evaluating daratumumab‐based regimens in stage IIIb AL amyloidosis attached separately as Table S3 mini‐review.pdf Table S3. Mini‐review of key studies evaluating daratumumab‐based regimens in patients with stage IIIb AL amyloidosis, including reported hematologic responses, cardiac responses, and survival outcomes.
Data Availability Statement
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
References
- 1. Kastritis E., Palladini G., Minnema M. C., et al., “Daratumumab‐Based Treatment for Immunoglobulin Light‐Chain Amyloidosis,” New England Journal of Medicine 385, no. 1 (2021): 46–58, 10.1056/NEJMoa2028631. [DOI] [PubMed] [Google Scholar]
- 2. Sanchorawala V., “Systemic Light Chain Amyloidosis,” New England Journal of Medicine 390, no. 24 (2024): 2295–2307, 10.1056/NEJMra2304088. [DOI] [PubMed] [Google Scholar]
- 3. Dispenzieri A., Gertz M. A., Kyle R. A., et al., “Serum Cardiac Troponins and N‐Terminal Pro‐Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis,” Journal of Clinical Oncology 22, no. 18 (2004): 3751–3757, 10.1200/JCO.2004.03.029. [DOI] [PubMed] [Google Scholar]
- 4. Wechalekar A. D., Schonland S. O., Kastritis E., et al., “A European Collaborative Study of Treatment Outcomes in 346 Patients With Cardiac Stage III AL Amyloidosis,” Blood 121, no. 17 (2013): 3420–3427, 10.1182/blood-2012-12-473066. [DOI] [PubMed] [Google Scholar]
- 5. Chakraborty R., Rosenbaum C., Kaur G., et al., “First Report of Outcomes in Patients With Stage IIIb AL Amyloidosis Treated With Dara‐VCD Front‐Line Therapy,” British Journal of Haematology 201, no. 5 (2023): 913–916, 10.1111/bjh.18733. [DOI] [PubMed] [Google Scholar]
- 6. Theodorakakou F., Briasoulis A., Fotiou D., et al., “Outcomes for Patients With Systemic Light Chain Amyloidosis and Mayo Stage 3B Disease,” Hematological Oncology 41, no. 4 (2023): 725–732, 10.1002/hon.3135. [DOI] [PubMed] [Google Scholar]
- 7. Oubari S., Hegenbart U., Schoder R., et al., “Daratumumab in First‐Line Treatment of Patients With Light Chain Amyloidosis and Mayo Stage IIIb Improves Treatment Response and Overall Survival,” Haematologica 109, no. 1 (2024): 220–230, 10.3324/haematol.2023.283325. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Bellofiore C., Basset M., Sanna G. D., et al., “Daratumumab‐Based Regimens Versus CyBorD in Newly Diagnosed Patients With AL Amyloidosis and IIIb Cardiac Stage: A Matched Case‐Control Study,” HemaSphere 9, no. 3 (2025): e70112, 10.1002/hem3.70112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Charliński G., Steinhardt M., Rasche L., et al., “Outcomes of Modified Mayo Stage IIIa and IIIb Cardiac Light‐Chain Amyloidosis: Real‐World Experience in Clinical Characteristics and Treatment‐67 Patients Multicenter Analysis,” Cancers 16, no. 8 (2024): 1592, 10.3390/cancers16081592. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Yohannan B., Rees M., Gertz M. A., et al., “Improved Survival With Daratumumab‐CyBorD Compared With CyBorD as Frontline Therapy for AL Amyloidosis,” Blood Neoplasia 2, no. 2 (2025): 100092, 10.1016/j.bneo.2025.100092. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Wang J., Li M., Liao P., et al., “Outcomes of Patients With Systemic Light Chain Amyloidosis Treated With DVD Front‐Line Therapy,” Cardio‐Oncology 12, no. 1 (2026): 34, 10.1186/s40959-026-00446-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Kastritis E., Minnema M. C., Dimopoulos M. A., et al., “Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients With Stage 3B Light Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network,” Blood 144 (2024): 1979, 10.1182/blood-2024-202932.39509120 [DOI] [Google Scholar]
- 13. Shen K. N., Gao Y. J., Chang L., et al., “Efficacy and Safety of Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Mayo 2004 Stage IIIA or IIIB Light‐Chain Amyloidosis: A Prospective Phase II Study,” Haematologica 109, no. 7 (2024): 2355–2358, 10.3324/haematol.2024.285145. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Palladini G., Dispenzieri A., Gertz M. A., et al., “New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 30, no. 36 (2012): 4541–4549, 10.1200/JCO.2011.37.7614. [DOI] [PubMed] [Google Scholar]
- 15. Palladini G., Schönland S. O., Sanchorawala V., et al., “Clarification on the Definition of Complete Haematologic Response in Light‐Chain (AL) Amyloidosis,” Amyloid: The International Journal of Experimental and Clinical Investigation 28, no. 1 (2021): 1–2, 10.1080/13506129.2020.1868810. [DOI] [PubMed] [Google Scholar]
- 16. Gertz M. A., Comenzo R., Falk R. H., et al., “Definition of Organ Involvement and Treatment Response in Immunoglobulin Light Chain Amyloidosis (AL): A Consensus Opinion From the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004,” American Journal of Hematology 79, no. 4 (2005): 319–328, 10.1002/ajh.20381. [DOI] [PubMed] [Google Scholar]
- 17. Palladini G., Barassi A., Klersy C., et al., “The Combination of High‐Sensitivity Cardiac Troponin T (Hs‐cTnT) at Presentation and Changes in N‐Terminal Natriuretic Peptide Type B (NT‐proBNP) After Chemotherapy Best Predicts Survival in AL Amyloidosis,” Blood 116, no. 18 (2010): 3426–3430, 10.1182/blood-2010-05-286567. [DOI] [PubMed] [Google Scholar]
- 18. Muchtar E., Dispenzieri A., Wisniowski B., et al., “Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 41, no. 7 (2023): 1393–1403, 10.1200/JCO.22.00643. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Basset M., Milani P., Foli A., et al., “Early Cardiac Response Is Possible in Stage IIIb Cardiac AL Amyloidosis and Is Associated With Prolonged Survival,” Blood 140, no. 18 (2022): 1964–1971, 10.1182/blood.2022016348. [DOI] [PubMed] [Google Scholar]
- 20. Chakraborty R., Kastritis E., Huart A., et al., “Phase 1/2 Dose Escalation and Expansion Study of Etentamig in Patients With Relapsed or Refractory Light Chain Amyloidosis,” Blood 146, no. Supplement 1 (2025): 692, 10.1182/blood-2025-692. [DOI] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data S1: ajh70416‐sup‐0001‐Supinfo.docx.
Table S1: 1st year hospitalization data attached separately as Table S1 CUIMC hospitalization Data.pdf Table S1. First‐year hospitalization data for 41 patients following treatment initiation at Columbia University Irving Medical Center (CUIMC).
Table S2: Univariate analysis for overall survival (OS) using Cox proportional hazards models attached separately as Table S2 univariate analysis Cox.pdf Table S2. Univariate analysis of factors associated with overall survival (OS) using Cox proportional hazards models.
Table S3: Mini‐review of key studies evaluating daratumumab‐based regimens in stage IIIb AL amyloidosis attached separately as Table S3 mini‐review.pdf Table S3. Mini‐review of key studies evaluating daratumumab‐based regimens in patients with stage IIIb AL amyloidosis, including reported hematologic responses, cardiac responses, and survival outcomes.
Data Availability Statement
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.